Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501).
Fabien FrancoisLoubna NaimiXavier RoblinAnne-Emmanuelle BergerStephane PaulPublished in: BMC immunology (2021)
LISA-TRACKER ADA and anti-ADA assays are reliable for the monitoring of patients treated with ABP501.